OPTIMAS Trial: Early vs. Delayed Anticoagulation in Acute Ischemic Stroke with Atrial Fibrillation and Chronic Kidney Disease
Highlight
1. The OPTIMAS trial evaluated the timing of direct oral anticoagulant (DOAC) initiation after acute ischemic stroke (IS) in patients with atrial fibrillation (AF), stratified by chronic kidney disease (CKD) status.
2. Early DOAC initiation (within 4 days) compared to delayed initiation (days 7-14) showed no difference in recurrent ischemic stroke, intracranial hemorrhage, systemic embolism, or mortality in both CKD and non-CKD groups.
3. CKD does not modify the effect of early versus delayed anticoagulation initiation, supporting early treatment for stroke prevention in patients with AF regardless of kidney function.
4. These findings address safety concerns and may inform clinical guidelines to optimize anticoagulation timing in this high-risk population.
Study Background and Disease Burden
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.